Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.

Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally, and is Novo Nordisk's third drug in the class after daily injectable Victoza (liraglutide) and weekly shot Ozempic ...

GLP-1 (glucagon-like peptide-1) discovered in the 1980s functions as a hormone derived from the proglucagon sequence and was found to have a transformative impact on the treatment of diabetes and ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney ...

Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...